Zhu Dafu, Chen Jianglong, Zhang Li, Li Hongxu, Wang Jingyi, Song Jiacui, Weng Dong, Zhang Pengcheng, Li Qiuhong, Zhang Yuan, Zhao Mengmeng
Department of Pulmonary and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, 200433, China.
School of Biomedical Engineering, ShanghaiTech University, Shanghai, 201210, China.
BMC Pulm Med. 2025 Aug 2;25(1):373. doi: 10.1186/s12890-025-03863-y.
Sarcoidosis is a systemic inflammatory disease, primarily affecting the lungs, with a prognosis that varies widely among patients. While some patients recover spontaneously after diagnosis, others experience disease progression. Currently, the metabolomic profile associated with pulmonary sarcoidosis and its different clinical outcomes remains poorly understood.
Serum samples from 29 pulmonary sarcoidosis patients and 10 healthy controls were analyzed using untargeted UPLC-MS/MS metabolomics. Univariate and multivariate analyses identified differentially expressed metabolites, followed by pathway enrichment to evaluate their biological relevance. Patients were further stratified into self-healing (n = 11) and progressive (n = 18) subgroups based on prognosis. Differential metabolites between subgroups were compared, potential biomarkers were selected, and their diagnostic performance assessed. Correlations with clinical parameters were also analyzed to explore associations with disease progression.
Sarcoidosis patients showed distinct serum metabolic profiles compared to healthy controls, with 10 upregulated and 199 downregulated metabolites. Pathway analysis indicated enrichment in amino acid, lipid, and immune-related pathways. Between prognostic subgroups, 25 differential metabolites were identified. Uric acid, testosterone sulfate, allopregnanolone sulfate, and 24,25-dihydroxyvitamin D emerged as key metabolites with prognostic value and moderate correlations with clinical parameters.
This study highlights distinct serum metabolic profiles associated with sarcoidosis prognosis, suggesting that specific metabolic alterations may aid in monitoring and predicting disease outcomes. These findings offer a foundation for future research into personalized treatment and management strategies.
结节病是一种全身性炎症性疾病，主要影响肺部，患者的预后差异很大。虽然一些患者在诊断后会自发康复，但另一些患者会出现疾病进展。目前，与肺结节病及其不同临床结局相关的代谢组学特征仍知之甚少。
使用非靶向超高效液相色谱-串联质谱代谢组学分析了29例肺结节病患者和10名健康对照者的血清样本。单变量和多变量分析确定了差异表达的代谢物，随后进行通路富集以评估其生物学相关性。根据预后将患者进一步分为自愈组（n = 11）和进展组（n = 18）亚组。比较亚组之间的差异代谢物，选择潜在的生物标志物，并评估其诊断性能。还分析了与临床参数的相关性，以探索与疾病进展的关联。
与健康对照相比，结节病患者表现出独特的血清代谢谱，有10种代谢物上调，199种代谢物下调。通路分析表明在氨基酸、脂质和免疫相关通路中富集。在预后亚组之间，鉴定出25种差异代谢物。尿酸、硫酸睾酮、硫酸别孕烷醇酮和24,25-二羟基维生素D成为具有预后价值且与临床参数有中度相关性的关键代谢物。
本研究突出了与结节病预后相关的独特血清代谢谱，表明特定的代谢改变可能有助于监测和预测疾病结局。这些发现为未来个性化治疗和管理策略的研究提供了基础。
